Straumann Holding Signals Strong Growth Amid Transition

Straumann Holding ((CH:STMN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Straumann Holding’s latest earnings call struck an upbeat tone as management highlighted strong organic revenue growth, resilient margins, and solid cash generation despite significant currency and transition headwinds. Executives framed 2025 as a heavy investment and transformation year, but one that lays the groundwork for margin expansion and accelerated growth from 2026 onward.

Top-Line Expansion Outpaces Reported Growth

Straumann delivered revenue of CHF 2.6 billion for FY 2025, translating into organic growth of 8.9% as underlying demand remained robust across core implant and digital solutions. Reported growth of 4.1% was held back by roughly CHF 100 million of adverse currency translation, masking the strength of local-currency performance.

Margins Strengthen Despite FX Drag

Profitability improved, with core EBIT margin reaching 26.5% at constant 2024 exchange rates, or 25.2% after currency effects. The group posted a core gross margin of 70.1% and a core net result of CHF 478 million, corresponding to a healthy net margin of 18.3% and underscoring operating leverage in the model.

Solid Cash Flow in a Heavy CapEx Year

Free cash flow came in at CHF 290 million, equal to 11.1% of net revenue, demonstrating strong cash conversion even as Straumann advanced a major manufacturing build-out. Capital expenditures climbed to CHF 223 million, up CHF 56 million year on year, marking one of the highest investment levels in company history.

Blockbuster Launches and Rapid Digital Uptake

Innovation remained a key growth engine, led by the iEXCEL implant surpassing one million units sold, making it the most successful implant launch in the company’s history. In digital, the SIRIOS X3 intraoral scanner, introduced in October 2025, is seeing strong early traction, while Straumann AXS has already amassed more than 15,000 active users within 18 months.

Regional Engines Drive Growth

Regionally, EMEA stood out with organic growth above 11% for the full year and particular strength in the fourth quarter as adoption of new solutions accelerated. North America showed sequential improvement with Q4 organic growth of 6.8%, while Latin America delivered high double-digit growth of about 18% and contributed 17% of the group’s total organic expansion.

Orthodontics Transformation on Track

In orthodontics, the transition of ClearCorrect manufacturing to partner Smartee in EMEA and APAC is progressing as planned and is designed to reduce cost of goods sold from mid-2026 onward. Management also flagged upcoming product enhancements, including a scalloped trimline and mandibular repositioning features, aimed at boosting clinical performance and differentiation.

Sustainability and Education Strengthen Franchise

The group continued to invest in education and sustainability, training more than 370,000 dental professionals across some 10,700 programs, which supports long-term demand and practitioner loyalty. On the environmental side, Straumann cut Scope 1 and 2 CO2 emissions by about 17% versus 2021 and sourced 98.5% of its electricity from renewable sources.

Dividends Reflect Cash Strength

Straumann’s capital allocation remained balanced, with the Board proposing a dividend of CHF 1.00 per share, up 5% from the prior year and implying a core payout ratio of roughly 33%. The move underscores the company’s confidence in its cash-generating ability while still funding growth investments and capacity expansion.

China Softness and VBP Overhang

Not all regions were smooth, as China weakened in the second half of 2025 due to softer patient flow and distributor destocking ahead of the value-based procurement process. Management expects these headwinds to persist into the first half of 2026, with a potential recovery in the second half depending on VBP timing and normalization of channel inventories.

Currency and Translation Hit Visibility

Foreign exchange remained a significant swing factor, with reported revenue growth of 4.1% lagging the 8.9% organic increase because of translation effects. Currency movements also reduced EBIT margins by about 130 basis points and cut reported revenue growth by roughly 480 basis points versus local-currency trends, adding noise to headline numbers for investors.

Tariffs and Cost Inflation Pressure Margins

Gross margins were further weighed down by U.S. tariffs and costs related to ramping up production in Shanghai, highlighting a less benign cost backdrop. Tariffs alone produced an estimated P&L impact of around CHF 20 million in 2025, with a similar or slightly higher drag expected in 2026 and a roughly even split between the first and second half.

Restructuring and Non-Core Charges Burden IFRS

Below the core line, Straumann booked non-core items totaling about CHF 120 million after tax, tied to restructuring, acquisition-related amortization, legal matters, and impairments linked to headquarters relocation and production transfers. These charges weighed on IFRS reported results and temporarily clouded the underlying profitability progress.

Transition Costs Depress Short-Term Margins

The company’s heavy investment year also brought transition-related double costs from ClearCorrect production wind-down, Shanghai ramp-up, and completion of the Curitiba facility. While these moves are aimed at boosting long-term efficiency and capacity, they created short-term margin pressure and complicate year-on-year comparisons during the transition period.

Orthodontics Creates Near-Term Margin Drag

Within orthodontics specifically, the ClearCorrect transformation has led to additional temporary costs as manufacturing shifts to Smartee, limiting segment profitability near term. Management signaled that margin comparability in the first half will remain challenging, but they expect the cost benefits to start contributing visibly from the second half of 2026.

Reported Metrics Trail Local-Currency Performance

The gap between reported and organic growth has become a recurring theme, with translation and FX effects softening CHF-reported figures relative to local-currency momentum. This divergence adds volatility for investors tracking headline numbers, even as operational performance, market share gains, and product adoption trends remain solid underneath.

Guidance Points to Steady Growth and Margin Gains

Looking ahead to 2026, Straumann guided to high single-digit organic revenue growth and a core EBIT margin expansion of 30–60 basis points at constant 2025 exchange rates, assuming the China procurement process takes place around the second quarter. The outlook is underpinned by lower CapEx and working capital needs, significantly reduced non-core items, ramping margin benefits from Smartee-driven orthodontic COGS savings, continued digital and manufacturing efficiencies, and sustained market-share gains in a more than CHF 20 billion addressable market.

Straumann’s earnings call painted the picture of a business absorbing short-term friction from FX, tariffs, and transformation costs while continuing to grow and invest for scale. For investors, the key takeaway is that underlying demand and innovation remain robust, and if execution on the manufacturing and orthodontic transitions stays on track, the company appears well positioned for improving margins and durable growth beyond 2026.